Moreover, there is a knowledge gap regarding the interactions between newer classes of diabetes medications, such as SGLT-2 inhibitors and GLP-1 receptor agonists, with specific types of carbohydrates. The gene discussed is GLP1R; the disease is diabetes mellitus.